AGENDA AT GLANCE
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Navigating the Evolving RNA Therapeutic Landscape in Asia:
Regulatory Challenges, Strategic Partnerships, and Emerging Opportunities
9:00
Leadership Panel Discussion: Assessing the Current RNA Therapeutics Landscape: Challenges and Opportunities
- Exploring recent breakthroughs in RNA drug development, including mRNA vaccines, RNA interference, and gene editing techniques
- Reviewing the current regulatory framework for RNA-based therapeutics and the challenges faced in obtaining approvals for new RNA therapies
- Examining the hurdles in the large-scale production and distribution of RNA therapeutics, and the solutions being explored to overcome these barriers
- Discussing how RNA therapeutics can be tailored for personalized treatments, and their potential in revolutionizing healthcare through targeted therapies for genetic disorders, cancer, and more
- Cross-border collaboration in addressing emerging diseases
Moderator:
👤 Andreas Donny Prakasa, Head of Corporate Relationship, PT Etana Biotechnologies, Indonesia
Panelists:
👤 Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia
👤 Vaibhav Dubey, General Manager, Kashiv BioSciences, India
👤 Volker Patzel, Assistant Professor, National University of Singapore, Singapore
9:45
Advancing RNA Therapeutics: Southeast Asia’s Emerging Landscape and Australia’s Strategic Role
- Southeast Asia is emerging as a hub for RNA therapeutics, with Thailand and Singapore leading develpoment and GMP manufacturing through organisations like SCG Cell Therapy and A*STAR
- Technological advances in RNA synthesis, purification and scalable production are enabling broader adoption of RNA-based treatments and personalised medicine
- Australia is a key contributor to RNA innovation, supported by national initiaves such as RNA Blueprint and Medical Science Co-investment Plan, which foster research, regulation and global collaboration
👤 Helen Oh, Regional Co-Lead for Critical Tech and Health, Australian Trade and Investment Commission, Singapore
10:10
Strengthening mRNA vaccine development capacity in Malaysia
- Malaysia’s national vaccine agenda: Coordinated initiatives and multi-stakeholder efforts to achieve self-reliance
- Upstream mRNA development for neglected diseases: Current progress, challenges and capability gaps
- Strategies to strengthen R&D, bioprocessing, preclinical and manufacturing for sustainable vaccine development
👤 Natasha Lee Hai Yen, Senior Lecturer, Universiti Malaya, Malaysia
10:35
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Optimizing RNA Synthesis for Scalable Therapeutic Production
11:05
Minimalistic non-viral DNA vectors expressing computationally designed functional RNA for gene therapy, mitochondrial gene therapy, and genetic vaccination
- Design and manufacture of minimalistic, dumbbell-shaped, non-viral DNA delivery vectors
- Computational design of functional RNA
- Application of non-viral vectors for gene therapy and genetic vaccination
👤 Volker Patzel, Assistant Professor, National University of Singapore, Singapore
11:30
Reserved for Service Provider
11:55
Formulation and Process Development Strategies for Scalable mRNA Therapeutics
👤 Vaibhav Dubey, General Manager, Kashiv BioSciences, India
12:20
Lunch, Exhibition Viewing & 1-1 Attendees Networking
RNA Mechanisms and Modulation: From Cellular Regulation to Synthetic Applications
1:20
Unlocking RNA Splicing: Mechanisms and Implications for Therapeutic Development
- Understanding the key mechanisms of RNA splicing, including the roles of spliceosomes and alternative splicing in gene expression
- How targeting RNA splicing can be leveraged to develop novel therapies, particularly for genetic diseases and cancers
- Exploring diseases caused by splicing defects, such as certain neurodegenerative and muscular disorders, and how therapies are being developed to correct these defects
- Technical and biological hurdles in manipulating splicing processes, including off-target effects and delivery mechanisms
1:45
Advancing Kidney-Targeted siRNA Therapies: Precision Delivery and NHP Proof-of-Concept
👤 Ryan Huang Yuanyu, Founder, Chairman & Chief Scientist Officer, Rigerna Therapeutics, China
2:10
Logic‑Gated mRNA: Programmable RNA Sensors for Precision Therapeutics
👤 Sophia Lugo, CEO & Chairman, Radar Therapeutics, USA
2:35
MicroRNAs and Gene Expression in Cognitive Health and Chronic Disease: Epigenetic Insights from Lifestyle and Intergenerational Studies
- Role of physical activity in modulating miRNA expression linked to cognitive function and chronic disease outcomes
- Mechanisms by which specific microRNAs regulate gene expression in lifestyle-related disorders
- Epigenetic and intergenerational impacts of miRNA expression patterns in long-term disease risk and healthspan
👤 Vimolmas Tansathitaya, Assistant Professor, Mahidol University, Thailand
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Case Study & Insights from Asia in Scaling RNA-Based Therapies
3:30
Establishing Asia’s First mRNA Vaccine Manufacturing Ecosystem: Lessons from Technology Transfer & Scale-Up
👤 Andreas Donny Prakasa, Head of Corporate Relationship, PT Etana Biotechnologies, Indonesia
3:55
Unlocking the Next Wave of mRNA-Based Vaccines, Therapeutics & Platforms in Asia: Advancing mRNA Drugs Towards Clinical Reality
This is your chance to hear from pioneering leaders in the mRNA space across Asia, who will share their insights on the ambitions, strategies, and challenges in advancing mRNA technology. The discussion will focus on identifying unmet needs, promising indications, and the development of the next generation of mRNA medicines.
Key Discussion Points:
- What are the emerging opportunities, promising targets, and applications for mRNA technology in Asia that could drive clinical success?
- What are the biggest challenges in balancing scientific innovation with strategic pipeline management as we approach 2025?
- How can mRNA companies in Asia reduce risks, extend cash flow, and position themselves to become attractive, investable SMEs?
- What lessons can be learned from Asia's rapidly evolving mRNA landscape to foster growth and global impact in this sector?
Panelists:
👤 Zeng Xian, CEO & Co-Founder, Byterna Therapeutics, China
👤 Ying Bo, CEO, Abogen Biosciences, China
👤 Wonil Kim, Chief Scientific Officer (CSO), Aston Sci., S.Korea
4:45
RNAi-Based Approaches in Aquaculture: Advancing RNA Technologies Beyond Human Therapeutics
👤 Dr. Vanvimon Saksmerprome, Principal Researcher, National Center for Genetic Engineering and Biotechnology, Thailand
5:10
Chairman Closing Remarks
5:15
End of day 1 conference & Networking Cocktail
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
Novel RNA Modalities and Indications: Advancements, Challenges, and Recent Breakthroughs
9:00
AI-Driven In Silico Epitope Screening for mRNA-Based Cancer Vaccine Development
- Th-Vac® is an AI-powered system designed to help create mRNA cancer vaccines that activate CD4+ helper T cells
- mRNA cancer vaccines can specifically target cancer-associated antigens such as TROP2, PD-L1, IDO, and KRAS
- Th-Vac® aims to address current challenges in cancer immunotherapy and enhance future treatment options
👤 Wonil Kim, Chief Scientific Officer (CSO), Aston Sci., S.Korea
9:25
Next-Gen Polymer/Lipid Based Delivery Systems for RNA Therapeutics
👤 Madhavan Nallani, Founder & CEO, ACM Biolabs, Singapore
9:50
Advancing cmRNA Therapeutics: Innovations in In Vivo CAR‑T Cell Therapy
- Innovations in cmRNA technology and their potential in nest-generation mRNA therapeutics
- CellectLNP Platform for efficient extra-hepatic and T-cell targeted delivery of cmRNA for in vivo cell engineering
- Robust B-cell depletion of cmRNA-based in vivo CAR-T supports its promising future in autoimmune diseases treatment
👤 Zeng Xian, CEO & Co-Founder, Byterna Therapeutics, China
10:15
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
RNA Delivery: Innovative Mechanisms and Therapeutic Applications
10:45
Panel Discussion: Advancing RNA Delivery Systems: Enhancing Efficiency and Precision
- Overview of current RNA delivery technologies and their limitations.
- Emerging innovations in lipid nanoparticles (LNP) and alternative delivery systems.
- Strategies for improving tissue targeting and minimizing off-target effects.
- Regulatory challenges and considerations for novel RNA delivery systems.
Moderator:
👤 Aprilia Paramitasari, Medical Doctor, Taipei Medical University, Taiwan
Panelists:
👤 Ryan Huang Yuanyu, Founder, Chairman & Chief Scientist Officer, Rigerna Therapeutics, China
👤 Poon Hung Fai, CEO, Sirnaomics, China
👤 Madhavan Nallani, Founder & CEO, ACM Biolabs, Singapore
11:15
Designing and Optimising RNA Delivery Platforms for Targeted Therapeutic Applications
- The critical role of designing delivery platforms in RNA Therapeutics to align with desired immune outcomes
- Directing RNA carriers to specific immune cells to help fine-tune immune responses across various disease settings.
- Incorporating immune insights into RNA and delivery design to support the advancement of more refined RNA therapies.
👤 Aprilia Paramitasari, Medical Doctor, Taipei Medical University, Taiwan
11:40
Delivery of mRNA for Vaccines, Cancer and Autoimmune Diseases
- Introduction of Abogen's RNA technology platform
- Next-Gen LNP for safe and effective delivery of mRNA in mice and NHP
- Clinical updates of Abogen's research in vaccines, cancer and autoimmune diseases
👤 Ying Bo, CEO, Abogen Biosciences, China
12:05
Innovative Delivery Platforms for siRNA Therapeutics
- Proprietary Delivery Tech: PNP and GalNAc platforms enabling precise siRNA targeting for cancer, fibrosis, and more.
- Clinical Highlights: STP705 (Phase IIb/III) and STP122G (Phase I) showing strong efficacy and safety data.
- Next-Gen Innovations: Expanding to CNS, lung, and gut with novel approaches like AODC for broader RNAi therapy.
👤 Poon Hung Fai, CEO, Sirnaomics, China
12:30
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Next-Gen RNA Platforms: Enabling Innovation in Therapeutics and Manufacturing
1:30
Innovating Genetic Medicine: Combining RNA Therapeutics with CRISPR for Cystic Fibrosis and Beyond
- How the integration of RNA therapies and CRISPR is showing promise in treating cystic fibrosis at the genetic level
- How RNA and CRISPR can enable personalized treatment plans for genetic conditions, tailored to an individual's mutation profile
- Regulatory, technical, and financial challenges in moving these therapies from lab to patient
- The future landscape for CRISPR and RNA therapies in treating other genetic disorders, such as sickle cell anemia and Duchenne muscular dystrophy
👤 Reserved for Fadinda Shafira, AI Engineer, PT Kalbe Farma, Indonesia
1:55
Translating siRNA and Gene Therapy Innovation into Clinical Success
👤 Adam Zhao Chunlin, CEO & Chairman, Anlong Bio, China
2:20
👤 Reserved for Chantelle Ahlenstiel, Senior Research Fellow, Kirby Institute, UNSW, Australia
2:45
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Future Directions in RNA Therapeutics: Trends and Innovations
3:15
Public Health Preparedness with mRNA and Viral Vectors: Building Capabilities at the National Level
👤 Indra Rudiansyah, Project Leader for mRNA and Viral Vector Vaccines Programme, PT Bio Farma, Indonesia
3:40
Clinical Development Strategies for RNA-Based Vaccines: From Candidate Selection to Regulatory Readiness
- Adaptive and Accelerated Trial Designs
- Endpoint Selection and Immunogenicity Assessment
- Safety Monitoring and Risk Mitigation
👤 Subhash Thuluva, Senior VP & Head-Clinical Development, Biological E. Limited, India
4:05
Next-Generation RNA Therapeutics & Diagnostics: Advancements, Platforms, and Fast-Tracked Applications
- Overview of emerging RNA technologies and scientific platforms, including RNA editing, self-amplifying RNA, and synthetic biology
- How RNA biology is evolving to support more precise and effective RNA-based therapeutics and diagnostics
- Key RNA approaches and therapeutic indications (small and long RNAs) currently fast-tracked for clinical use, with a focus on cancer, genetic disorders, and infectious diseases
- What steps are being taken to scale RNA therapies and diagnostics, from technology development to clinical adoption, including regulatory challenges and manufacturing innovations
Moderator:
👤 Subhash Thuluva, Senior VP & Head-Clinical Development, Biological E. Limited, India
Panelists:
👤 Adam Zhao Chunlin, CEO & Chairman, Anlong Bio, China
👤 Indra Rudiansyah, Project Leader for mRNA and Viral Vector Vaccines Programme, PT Bio Farma, Indonesia
4:35
Advancing Regional RNA Innovation through Strategic Collaboration and Research Translation
👤 Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia
5:00
Chairman Closing Remarks
5:05
End of day 2 conference
For Speaking Opportunities, Kindly Contact:
Lara Santiago
Senior Portfolio Specialist
[email protected] | +63 91762 10686
Share With Your Network
